CoChat

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Open access

The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index; 38 of the 156 sources its claims cite were checked for support.

Abstract

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.

Overview

CoChat Summary

TL;DR

This narrative review summarizes evidence that GLP-1 receptor agonists improve weight, liver enzymes, steatosis, and steatohepatitis in NAFLD/NASH, with some signals for reduced fibrosis progression. It concludes that long-term human trials are still needed, especially for pre-existing fibrosis and HCC outcomes.

Key findings

  • NAFLD is described as the most frequent liver disease, with a global estimated prevalence of 32.4% and affecting up to 70% of patients with diabetes; no specific drug treatment is currently available.
  • GLP-1 RAs reduce body weight by about 1.5–6 kg or 2–7 kg depending on agent/dose, lower HbA1c by 0.8–1.9%, and are associated with a 9–16% reduction in cardiovascular events and all-cause mortality.
  • In NASH trials, liraglutide achieved histological resolution of steatohepatitis in 39% vs 9% with placebo and reduced fibrosis progression (9% vs 36%, p = 0.04); semaglutide 0.4 mg/day achieved NASH resolution in 59% vs 17% with placebo and fibrosis progression in 5% vs 19%.
  • Semaglutide 2.4 mg/week produced mean weight loss of 15.8% vs 6.4% with liraglutide in STEP 8, with >10% weight loss in 70.9% vs 25.6%, respectively.

Methods

  • Narrative review of currently available evidence on GLP-1 RAs in NAFLD, including clinical trials, meta-analyses, observational data, and preclinical studies.
  • The authors synthesize effects on body weight, hepatic cytolysis, steatosis, fibrosis, inflammation, and potential mechanisms, and discuss future dual/triple agonist perspectives.
  • No systematic search strategy, formal quality assessment, or meta-analysis is described in the text.

Limitations

  • The paper states that long-term trials evaluating GLP-1 RAs for reducing liver fibrosis are not currently available, and most fibrosis data come from indirect markers such as APRI, NFS, FIB-4, or liver stiffness.
  • The paper states it is unknown whether benefits are direct or mediated by drug-induced weight loss, and several mechanistic hypotheses require further investigation.
  • Evident from the text: this is a narrative review without a described systematic search or risk-of-bias assessment, and it relies on heterogeneous studies, including preclinical models and post hoc analyses.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms24021703

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1 Direct and indirect mechanisms of action of GLP-1 RAs potentially involved in the NAFLD treatment. ER: endoplasmic reticulum; FAs: fatty acids; FAM3A: family with sequence similarity 3 member A; FXR: farnesoid X receptor; HbA1c: glycosylated hemoglobin; LXR: liver X receptor. * also determined by the reduction in body weight.
Figure 1 Direct and indirect mechanisms of action of GLP-1 RAs potentially involved in the NAFLD treatment. ER: endoplasmic reticulum; FAs: fatty acids; FAM3A: family with sequence similarity 3 member A; FXR: farnesoid X receptor; HbA1c: glycosylated hemoglobin; LXR: liver X receptor. * also determined by the reduction in body weight.CC BY · PubMed Central

Verification

Claims the paper makes

25 Valid · 3 Not valid · 81 Not checked · 13 Own results and interpretations

67 more claims · 15 with their cited sources checked

Create a free account to see all 122 claims and to verify the 118 references still open.

See all claims — free account
  • It may state two separate claims as one. 46
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

1 retracted

Show all 176 references

Cited by

See all 315

Metadata

Authors
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C.
Affiliations
University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
Sasso, Ferdinando Carlo
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-01-15
Volume
24
Issue
2
Pages
1703
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4316664733
Cited by
286
References
178
Citations by year
2026: 77 · 2025: 108 · 2024: 75 · 2023: 26
FWCI
11.13
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
GLP-1 receptor agonists, non-alcoholic fatty liver disease, diabetes mellitus, liver fibrosis, weight loss, cardioprotection, renal protection, hypoglycemic effect, NAFLD treatment
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Liver, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. https://app.cochat.ai/papers/10.3390/ijms24021703
The paper
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021703

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.